MYD88 and neoplasm: However, the immunogenicity of tumor cells exposed to ICD-inducer is lost in mice presenting with genetic defects in TLR4 or MYD88, suggesting not all tumor cells will ultimately elicit an antitumor-specific T-cell immunity in the presence of ICD-inducer such as chemotherapy or radiotherapy [56].